NASDAQ | ETF
The adviser employs a "passive management" investment approach designed to track the total return performance of the index.
The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business.
The fund invests at least 80% of its net assets in DNA Modification Technology Companies.
It is non-diversified.
Top 10 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| CRSP | Crispr Therapeutics AG | Healthcare | Biotechnology | 14.70% |
| BEAM | Beam Therapeutics Inc | Healthcare | Biotechnology | 13.36% |
| TMO | Thermo Fisher Scientific Inc | Healthcare | Diagnostics & Research | 9.93% |
| NTLA | Intellia Therapeutics Inc | Healthcare | Biotechnology | 8.73% |
| PRME | Prime Medicine Inc. Common Stock | Healthcare | Biotechnology | 6.05% |
| EDIT | Editas Medicine Inc | Healthcare | Biotechnology | 5.87% |
| CRBU | Caribou Biosciences Inc | Healthcare | Biotechnology | 4.94% |
| VERV | Verve Therapeutics Inc | Healthcare | Biotechnology | 4.35% |
| PSTX | Poseida Therapeutics Inc | Healthcare | Biotechnology | 4.28% |
| ABBV | AbbVie Inc | Healthcare | Drug Manufacturers - General | 4.01% |